Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters

Area of Science:

• Pharmacology
• Molecular Biology
• Genetics

Background:

• Yondelis (trabectedin) is a DNA-binding anticancer agent derived from Ecteinascidia turbinata.
• Previous studies indicate Yondelis selectively inhibits the transcriptional induction of specific genes.

Purpose of the Study:

• To investigate whether Yondelis specifically targets cell-cycle genes.
• To elucidate the molecular mechanisms underlying Yondelis' selective gene expression effects.

Main Methods:

• Analysis of endogenous and reporter gene systems to assess transcriptional changes.
• Chromatin immunoprecipitation (ChIP) assays to evaluate nuclear factor Y (NF-Y) binding in vivo.
• Assessment of histone acetylation levels on specific gene promoters.

Main Results:

• Yondelis demonstrated complex transcriptional effects, including both inhibition and activation, particularly on cell-cycle genes.
• Metallothionein and CYP3A4 promoters were largely unaffected by Yondelis.
• NF-Y binding to DNA was minimally impacted by Yondelis treatment.
• Histone acetylation was modestly altered only for Cdc2 and cyclin B2 promoters.

Conclusions:

• Yondelis does not act as a general inhibitor of inducible genes.
• The drug's selective gene expression modulation occurs downstream of transcription factor binding and histone acetyltransferase recruitment.